Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human DS3790a (CD37-targeting DXd-ADC) in hematological malignancies
jRCT2031250487Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jan 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial of DS3790a in hematopoietic malignancies and mature B-cell lymphoma (8 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Safety and tolerability (dose-limiting toxicities and adverse events), Complete response by BICR (Cohort A Randomization/Optimization Phase, Cohort A Phase 2) and 1 more. Started Jan 2026; status: recruiting.
02
Drugs
DS3790a
03
Conditions
hematopoietic malignanciesmature B-cell lymphoma
Beyond the preview
Go deeper on jRCT2031250487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250487.